JP2012176956A5 - - Google Patents

Download PDF

Info

Publication number
JP2012176956A5
JP2012176956A5 JP2012092614A JP2012092614A JP2012176956A5 JP 2012176956 A5 JP2012176956 A5 JP 2012176956A5 JP 2012092614 A JP2012092614 A JP 2012092614A JP 2012092614 A JP2012092614 A JP 2012092614A JP 2012176956 A5 JP2012176956 A5 JP 2012176956A5
Authority
JP
Japan
Prior art keywords
group
substituted
hydroxy
composition according
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012092614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012176956A (ja
JP5969255B2 (ja
Filing date
Publication date
Priority claimed from US10/754,547 external-priority patent/US20050154046A1/en
Application filed filed Critical
Publication of JP2012176956A publication Critical patent/JP2012176956A/ja
Publication of JP2012176956A5 publication Critical patent/JP2012176956A5/ja
Application granted granted Critical
Publication of JP5969255B2 publication Critical patent/JP5969255B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012092614A 2004-01-12 2012-04-16 炎症関連疾患の治療法 Expired - Fee Related JP5969255B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/754,547 2004-01-12
US10/754,547 US20050154046A1 (en) 2004-01-12 2004-01-12 Methods of treating an inflammatory-related disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006549356A Division JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014240778A Division JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Publications (3)

Publication Number Publication Date
JP2012176956A JP2012176956A (ja) 2012-09-13
JP2012176956A5 true JP2012176956A5 (enExample) 2013-11-14
JP5969255B2 JP5969255B2 (ja) 2016-08-17

Family

ID=34739408

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006549356A Expired - Fee Related JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法
JP2012092614A Expired - Fee Related JP5969255B2 (ja) 2004-01-12 2012-04-16 炎症関連疾患の治療法
JP2014240778A Pending JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006549356A Expired - Fee Related JP5383977B2 (ja) 2004-01-12 2005-01-06 炎症関連疾患の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014240778A Pending JP2015071626A (ja) 2004-01-12 2014-11-28 炎症関連疾患の治療法

Country Status (15)

Country Link
US (2) US20050154046A1 (enExample)
EP (3) EP2351564B1 (enExample)
JP (3) JP5383977B2 (enExample)
CA (2) CA2547963C (enExample)
CY (1) CY1115289T1 (enExample)
DK (1) DK1706112T3 (enExample)
ES (2) ES2559183T3 (enExample)
HK (1) HK1220612A1 (enExample)
HR (1) HRP20140536T1 (enExample)
ME (1) ME01878B (enExample)
PL (1) PL1706112T3 (enExample)
PT (1) PT1706112E (enExample)
RS (1) RS53372B (enExample)
SI (1) SI1706112T1 (enExample)
WO (1) WO2005069933A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
AU2006242651B2 (en) * 2005-04-29 2013-05-16 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE602006009834D1 (de) 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
WO2007033208A2 (en) * 2005-09-12 2007-03-22 University Of Maryland Biotechnology Institute Off. Of Research Admin/Tech. Dev. Use of indirubin and its derivatives in the treatments of hiv infection and heart failure
EP2061446A2 (en) * 2006-07-28 2009-05-27 University Court of the University of Edinburgh Use of cdk inhibitors for the treatment of granulocyte mediated disorders
AU2008296487A1 (en) 2007-08-28 2009-03-12 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
KR20110028457A (ko) * 2008-05-21 2011-03-18 뉴로테즈 인코포레이티드 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
EP2193790A1 (en) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3 Inhibitors in use for treatment of rheumatoid arthritis in an early stage
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
WO2011127175A1 (en) * 2010-04-06 2011-10-13 Isis Pharmaceuticals, Inc. Modulation of cd130 (gp130) expression
CN102614122B (zh) * 2011-01-28 2013-10-16 上海现代药物制剂工程研究中心有限公司 酮咯酸氨丁三醇鼻腔喷雾剂及其制备方法
US8632827B2 (en) 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
JP6382187B2 (ja) * 2012-06-21 2018-08-29 フォスフォレックス，インコーポレーテッド インジルビンのナノ微粒子、その誘導体およびそれらを作製しかつ利用する方法
WO2014093053A1 (en) * 2012-12-11 2014-06-19 Avon Products, Inc. Modulation of thymosin beta-4 in skin
AU2014236370C1 (en) * 2013-03-14 2019-01-17 City Of Hope 5-bromo-indirubins
CN103333161B (zh) * 2013-05-28 2015-09-30 滁州市洛达生物科技有限公司 1’-氧代靛玉红的制备和用途
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
KR101832864B1 (ko) 2013-11-06 2018-02-27 와트 퓨얼 셀 코퍼레이션 기체 반응 매질 플로우 관리용 매니폴드를 가지는 화학 반응기
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2019142799A1 (ja) 2018-01-18 2019-07-25 学校法人慶應義塾 潰瘍性大腸炎治療カプセル剤
CN118515598A (zh) * 2018-12-07 2024-08-20 斯塔蒂亚生物制药有限公司 甲异靛的多晶型和甲异靛的改进制剂
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
WO2021146850A1 (en) * 2020-01-20 2021-07-29 Tsinghua University A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2021207489A1 (en) * 2020-04-08 2021-10-14 Rtu Pharmaceuticals, Llc Methods and pharmaceutical compositions to treat pulmonary inflammation in infected patients
US11345818B1 (en) 2020-12-29 2022-05-31 Industrial Technology Research Institute Dye for fiber and dyeing method
JP7880582B2 (ja) * 2021-07-13 2026-06-26 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
MX2024004264A (es) 2021-10-08 2024-07-10 Azora Therapeutics Inc Derivados de agonistas de los receptores de aril hidrocarburos.
CN116270616A (zh) * 2023-03-24 2023-06-23 上海交通大学医学院附属仁济医院 Carquinostatin A化合物在制备治疗炎症性肠病的药物中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995030A (en) * 1971-01-06 1976-11-30 Robert Daniels & Company, Inc. Composition and method for treating arthritis
US4172889A (en) * 1976-03-29 1979-10-30 The Upjohn Company Method of treating rheumatoid arthritis
US4118484A (en) * 1976-03-29 1978-10-03 The Upjohn Company Method of treating rheumatoid arthritis
US4049824A (en) * 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US4176179A (en) * 1978-04-17 1979-11-27 The University Of Virginia Alumni Patents Foundation Method for treating arthritis
US4468398A (en) * 1978-08-11 1984-08-28 Johnson Lewis A Method for treatment of rheumatoid arthritis
US4322405A (en) * 1981-04-06 1982-03-30 Laboratoires Om Societe Anonyme Method for treating rheumatoid arthritis
US4375468A (en) * 1981-07-13 1983-03-01 Verex Laboratories, Inc. Constant order release aspirin composition and method of treating arthritis
FR2516368B1 (fr) 1981-11-13 1985-06-21 Pigeon Daniel Meuble assemblable et demontable manuellement
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4500533A (en) * 1983-06-22 1985-02-19 Eli Lilly And Company 2,4,5-Triaryl pyrimidines and a method of treating pain, fever, thrombosis, inflammation and arthritis
US4533551A (en) * 1984-02-17 1985-08-06 American Home Products Corporation Method of treating arthritis with etodolac
JPS617254A (ja) 1984-06-20 1986-01-13 Isukura Sangyo Kk ビスインドリノンおよびそれを主成分とする制癌剤
MX168552B (es) * 1985-02-19 1993-05-31 Jensen Charles A Procedimiento para la preparacion de polvo mineral inorganico
US5026538A (en) * 1985-06-07 1991-06-25 Cadema Medical Products, Inc. Method of treating arthritis, including rheumatoid arthritis, with 166 Holmium radionuclide
US5061475A (en) * 1985-06-07 1991-10-29 Cadema Medical Products, Inc. Composition and method of treatment of arthritis and related diseases with holmium-166 radionuclides
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US4732752A (en) * 1986-10-23 1988-03-22 Peter Stephan Center, Ltd. Polyvalent equine immune serum composition and method for treating rheumatoid arthritis
US5782792A (en) * 1986-11-21 1998-07-21 Cypress Bioscience, Inc. Method for treatment of rheumatoid arthritis
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
US5061724A (en) * 1989-07-18 1991-10-29 Sheldon Gertner Method for treating arthritically inflamed body joints, particularly joints having gouty arthritis
US5149688A (en) * 1990-04-24 1992-09-22 Cetus Corporation Methods, compounds, and compositions for immunosuppression
US5511563A (en) * 1991-06-21 1996-04-30 Diamond; Donald A. Apparatus and method for treating rheumatoid and psoriatic arthritis
CA2087147A1 (en) * 1992-01-17 1993-07-18 William Drell Method for administration of azauridine for the treatment of rheumatoid arthritis
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
JP3565442B2 (ja) * 1993-04-22 2004-09-15 新日本石油化学株式会社 哺乳類の関節炎の診断剤および／または治療剤
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6033672A (en) * 1996-03-15 2000-03-07 University Of Southern California Method of stimulating an immune response to caprine arthritis-encephalitis virus (CAEV) in humans through the administration of CAEV immunogens
US5770357A (en) * 1996-03-15 1998-06-23 Univ Southern California Method of diagnosing caprine arthritis-encephalitis virus infection
US5843919A (en) * 1996-11-25 1998-12-01 Burger; John A. Composition and method for the treatment of arthritis
AU7408998A (en) * 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
US5952367A (en) * 1997-04-25 1999-09-14 Pak; Kyoungsik Method of treating pain cause by bursitis tendinitis arthritis
CA2289102A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US5849323A (en) * 1997-06-12 1998-12-15 A. Glenn Braswell Collagen mimetic and method of treating rheumatoid arthritis using same
US5849336A (en) * 1997-07-02 1998-12-15 Abbott Laboratories Method using sturgeon notochord for alleviating the symptoms of arthritis
US6610728B2 (en) * 1997-08-28 2003-08-26 Eli Lilly And Company Method for treatment of non-rheumatoid arthritis
US6040306A (en) * 1997-11-18 2000-03-21 Pharmacia & Upjohn Company Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy
EP1043998B1 (en) * 1997-12-13 2007-03-07 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS
KR100261114B1 (ko) * 1998-01-24 2000-07-01 박종헌 히스톤을 함유하는 류마티스 관절염 치료제 조성물
JP2002516851A (ja) 1998-05-29 2002-06-11 ゲルハルト アイゼンブランド サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用
AU768751B2 (en) * 1998-06-18 2004-01-08 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6524625B2 (en) * 1998-06-30 2003-02-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyuto Physiologically active extract obtained from indigo plant polygonum tinctorium
US6346519B1 (en) * 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6656925B2 (en) * 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
IL144675A0 (en) * 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
US6197776B1 (en) * 1999-03-17 2001-03-06 Ernest L. Bonner, Jr. Method for treatment of reactive arthritis or bursitis
US6087382A (en) * 1999-03-17 2000-07-11 Bonner, Jr.; Ernest L. Method for treatment of reactive arthritis or bursitis
EA200101046A1 (ru) 1999-04-12 2002-04-25 Герхард Айзенбранд Производные индигоидных бис-индолов
WO2000061124A2 (en) 1999-04-12 2000-10-19 Gerhard Eisenbrand Use off cell membrane penetrating indigoid bisindole derivatives
US6372794B1 (en) * 1999-08-26 2002-04-16 Marcel E. Nimni Method for alleviating arthritis in mammals
WO2001019819A2 (en) * 1999-09-14 2001-03-22 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
EP1110549A1 (en) * 1999-12-23 2001-06-27 Warner-Lambert Company Use of trimebutine for treating pain
JP2003531899A (ja) * 2000-05-03 2003-10-28 エルジー ライフ サイエンス リミテッド ３−ヒドロキシクロメン−４−オン構造を有するｃｄｋ阻害剤
AU2001290316A1 (en) * 2000-10-02 2002-04-15 Mochida Pharmaceutical Co., Ltd. Gata-3 expression inhibitor and method of screening the same
DE10053474A1 (de) * 2000-10-24 2002-05-02 Schering Ag Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
DE10061162A1 (de) * 2000-11-30 2002-07-11 Schering Ag Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
DE10114138C2 (de) * 2001-03-16 2003-03-27 Schering Ag Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit
DE10125763A1 (de) * 2001-05-17 2002-11-28 Schering Ag Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren
DE10129028A1 (de) * 2001-06-11 2003-01-02 Schering Ag Lösliche Cdk-inhibitorische Indirubinderivate
US6613800B1 (en) * 2001-12-03 2003-09-02 Steven A. Smith Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
US7582670B2 (en) * 2001-12-13 2009-09-01 Natrogen Therapeutics, Inc. Methods of treating an inflammatory-related disease
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US6566341B1 (en) * 2001-12-13 2003-05-20 Natrogen Therapeutics, Inc. Derivative of isoindigo, indigo and indirubin for the treatment of cancer
ATE484514T1 (de) * 2001-12-13 2010-10-15 Natrogen Therapeutics Inc Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
ATE478872T1 (de) * 2002-03-28 2010-09-15 Ustav Ex Botan Av Cr V V I I O Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
US20050090426A1 (en) * 2003-03-24 2005-04-28 Blumberg Richard S. Methods of inhibiting inflammation

Similar Documents

Publication Publication Date Title
JP2007522114A5 (enExample)
US20240180948A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
AU2021251689B2 (en) Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
JP2023133494A (ja) ステロイドの抗痙攣活性
JP2021165280A (ja) Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
CA3077739A1 (en) Lymphatic system-directing lipid prodrugs
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
JP2013541519A (ja) 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
TW201735924A (zh) 使用fxr促效劑之方法
TW201733583A (zh) Fxr促效劑之使用方法
TWI845826B (zh) 4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
US20260102422A1 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA2848979C (en) Conjugates comprising a plant steroid linked to a drug
JP2016516773A5 (enExample)
BR112014018393A8 (pt) Composição farmacêutica adequada para liberação ocular de um esteroide e uso da mesma para a fabricação de um medicamento para tratar uma doença oftálmica
WO2021263186A1 (en) Use of oxygenated cholesterol sulfates for treating inflammatory conditions
WO2022174179A9 (en) 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
Zhang et al. An O-benzyl phosphonamidate prodrug of tenofovir for the treatment of hepatitis B virus infection
CN111971049A (zh) 促进免疫应答
Turner et al. TPI 1020, a novel anti-inflammatory, nitric oxide donating compound, potentiates the bronchodilator effects of salbutamol in conscious guinea-pigs
CN115581697A (zh) 尼古丁及衍生物作为FXR-meglin/cublin调节剂在制备利胆产品中的应用
JP2019014684A5 (enExample)
CN102872029B (zh) Gypensapogenin B在制备促进小肠蠕动药物中的应用
CN102861028A (zh) Gypensapogenin B在预防或治疗胰腺纤维化的药物中的应用